Business Wire

EXSCIENTIA

15.6.2021 14:02:12 CEST | Business Wire | Press release

Share
Exscientia Acquires Personalised Medicine AI Pioneer Allcyte

Exscientia, a clinical stage pharmatech company, has entered into a binding agreement to acquire Allcyte, a leader in artificial intelligence (AI) based precision medicine. The combination expands Exscientia’s translational capabilities by enabling high content evaluation of individual patient biology in primary tumour tissues, rather than artificial cell lines or animal models. Allcyte’s platform has been validated on multiple solid and haematological tumour types as well as in non-cancerous tissues.

Pioneering work by Allcyte has delivered a platform able to anticipate the effectiveness of cancer treatments in the clinic by using AI to analyse the activity of drugs in live patient samples at single-cell resolution. In the first-ever1 prospective interventional study of its kind, EXALT-1, Allcyte’s approach predicted which therapy was to be most effective for late-stage haematological cancer patients based on drug activity in their own tissue samples. EXALT-1 demonstrated the real-world patient selection capabilities of Allcyte’s platform by achieving a 55% overall response rate and statistically significant improvement in progression free survival over the prior line of therapy. In a post hoc analysis, patients receiving therapy recommended by the platform showed significantly improved outcomes compared to their prior treatments (clinical benefit hazard ratio of 0.53; p=0.005), whereas patients who received treatments other than the platform recommended therapy showed worse outcomes (clinical benefit hazard ratio of 1.4; p=0.4)2 .

By joining Exscientia, Allcyte’s platform will be significantly expanded and extended into early discovery so that these ground-breaking technologies are applied from target discovery and drug optimisation to patient selection. This end-to-end approach will allow discovery projects to be assessed in a biological setting that more accurately reflects the actual patient environment, improving translation from laboratory to clinic.

“Allcyte is able to demonstrate what therapy actually works in the individual patient with the most disease relevant screening platform we have seen,” said Andrew Hopkins, Exscientia’s CEO. “Combining Allcyte’s platform with Exscientia’s technologies can redefine how drugs are developed, enabling integrated discovery and patient selection. Allcyte has assembled an outstanding team in Vienna and integration of the two platforms truly allows us to build our vision of patient-first AI.”

Commenting on the acquisition, Nikolaus Krall, Allcyte CEO added, “We are incredibly excited about the opportunity to immediately apply this technology to a wide range of drug discovery projects at Exscientia. This will also provide our team with the scale to expand our operations much more quickly to help provide important personalised, precision medicines to as many patients as possible.”

The transaction is currently being reviewed under the customary Austrian regulatory process prior to closing. Under the terms of the merger agreement, Exscientia will pay €50 million, comprising cash and Exscientia ordinary shares. Exscientia plans to expand the Vienna site as its hub in the European Union.

About Exscientia

Exscientia is an AI-driven pharmatech company committed to discovering and designing the best possible medicines in the fastest and most effective manner. Exscientia is the first company to progress AI-designed small molecules into the clinical setting and repeatedly demonstrate the ability of AI to transform how drugs are created. Exscientia’s AI platform has now designed three drugs that are in Phase 1 human clinical trials.

Drug design is precision engineering at the molecular scale. Exscientia has built dedicated AI systems that efficiently learn from the widest range of data and consistently reapply enhanced knowledge through iterations of design. Because Exscientia’s AI platform learns more effectively and rapidly than human-led efforts alone, candidate molecules satisfying complex therapeutic requirements are created with revolutionary efficiency. Exscientia believes that designing better drugs, faster, will allow the best ideas of science to rapidly become the best medicines for patients.

Exscientia has offices in Oxford, Miami, Osaka and Dundee. For more information visit us on www.exscientia.ai or follow us on Twitter @exscientiaAI.

About Allcyte

Allcyte is a Vienna, Austria-based precision medicine company whose mission is to ensure that every cancer patient gets the best possible treatment. Allcyte’s technology is designed to select the most promising drug candidates for clinical development in the right patient populations to maximise clinical study success rates and patient benefit. Clinically, Allcyte’s goal is to provide physicians with actionable insights on how to treat cancer patients with the right drug at the right time in situations where classical genetics-driven precision medicine does not give precise answers. This is achieved by measuring functional anticancer drug activity in viable, primary human patient tissues at the single cell resolution to gain a preview of likely clinical efficacy. Allcyte’s technology is the first AI platform to successfully improve cancer patient outcomes in a clinical trial.

For more information on the EXALT-1 trial, refer to
[1] the following Lancet Haematology article; https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30208-9/fulltext
[2] the following ASH abstract; https://ash.confex.com/ash/2020/webprogram/Paper140831.html

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Global EV Alliance Survey: EV Drivers Identify Myths and Misconceptions as the Biggest Barrier to Adoption17.11.2026 19:00:00 CET | Press release

Myths and misconceptions about electric cars, from battery lifespan and fire risk to grid collapse, are the biggest barrier to EV adoption, according to respondents to the annual Global EV Driver Survey. The 2026 survey draws on responses from more than 29,500 EV drivers across 34 countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117539716/en/ MYTHS. Battery lifespan (72%), fire risk (58%) and grid collapse (45%) top the list of EV myths reported by respondents to the 2026 Global EV Driver Survey, which gathered responses from more than 29,500 EV drivers across 34 countries. “The EV transition is not just an infrastructure or affordability challenge. It is also an information challenge. Outdated information and misconceptions continue to influence decisions long after the technology has moved on,” says Ellen Hiep, from the Steering Committee of the Global EV Alliance (GEVA). Myths the greatest barrier Asked to ide

TreeFrog Therapeutics Appoints James Sterling as Chief Financial Officer17.11.2026 18:04:00 CET | Press release

Seasoned biotech CFO with gene therapy, diagnostics, IPO and Wall Street experience joins the executive leadership team TreeFrog Therapeutics, a biotechnology company developing scalable cell therapies built on its proprietary C-Stem™ technology, today announced the appointment of James Sterling as Chief Financial Officer, effective November 1, 2026. James joins TreeFrog’s executive leadership team and reports to Mark Rothera, President and Chief Executive Officer. He oversees finance, investor relations and corporate development as the company enters its next phase of growth. “I am delighted to welcome James to TreeFrog. James brings a valuable combination of biotech CFO and Wall Street experience that supports our ambitions to develop TreeFrog into a key enabling partner and drug developer in the regenerative medicines field,” said Mark Rothera, President and Chief Executive Officer of TreeFrog Therapeutics. James contributes deep experience in corporate finance, capital markets and

Visa Report: AI-Enabled Fraud and Third-Party Attacks Are Scaling Worldwide17.11.2026 16:40:00 CET | Press release

Third-party incidents surged 62%, while Visa Scam Disruption identified more than $1.4 billion in potential fraud Fraud is becoming more automated, targeted and global as criminals use AI to exploit weak points across the payments ecosystem and target third-party providers that can provide access to multiple downstream payment organizations, according to the Visa (NYSE: V) Fall 2026 Biannual Threats Report released today during International Fraud Awareness Week. Developed by Visa Payment Ecosystem Risk and Control (PERC), the report examines threat activity observed between January and June 2026 and finds that AI is not creating entirely new categories of fraud. Instead, it is helping criminals that execute existing attacks faster, at greater scale, and with greater precision, while increasingly targeting third-party providers that can provide access to multiple downstream organizations at once. Although attack volumes increased in several areas, the report also found evidence that co

Sparxity Appoints former Cray CEO Peter Ungaro and Semiconductor Veteran Daniel Armbrust to its Advisory Board17.11.2026 16:00:00 CET | Press release

Appointments bring decades of leadership experience in supercomputing, semiconductor commercialization, and scaling advanced computing business Sparxity, a leader in sparse-native computing, today announced that Peter Ungaro, former President and CEO of Cray, Inc., and Daniel Armbrust, former President and CEO of SEMATECH and co-founder of Silicon Catalyst, have joined its Advisory Board as independent members. Armbrust has been elected Chairman of the Advisory Board and Ungaro Deputy Chairman by their fellow board members. The appointments strengthen the company’s leadership as it scales its sparse-native computing technology for next-generation AI and high-performance computing (HPC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117761685/en/ From left to right, Daniel Armbrust, former President and CEO of SEMATECH and co-founder of Silicon Catalyst and Peter Ungaro, former President and CEO of Cray, Inc. Peter Ungaro

SES to Develop European Direct-to-Device Technologies under ESA Partnership Project17.11.2026 15:30:00 CET | Press release

The new SELYCE programme supports transition towards hybrid networks to strengthen Europe’s critical communications infrastructures SES today announced it will lead the industrial activities of SELYCE, a new European initiative focused on developing the technologies needed to enable future Direct-to-Device (D2D) satellite services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117544892/en/ SES to Develop European Direct-to-Device Technologies under ESA Partnership Project Conducted under a Partnership Project with the European Space Agency (ESA) and supported by the Luxembourg Space Agency (LSA), Belgian Science Policy Office (BELSPO) and UK Space Agency (UKSA), SELYCE brings together European industry and research organisations to advance standards-based 5G Non-Terrestrial Network (NTN) capabilities that will allow everyday smartphones and IoT devices to connect seamlessly via satellite beyond the reach of terrestrial

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye